Mini-Focus Issue: Acute Myocardial InfarctionClinical ResearchPrediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) Trials
Clinical Research
Under an Elsevier user license
open archive
Key Words
infarct-related artery
major adverse cardiac events
percutaneous coronary intervention
stenting
stent thrombosis
ST-segment elevation myocardial infarction
SYNTAX score
target vessel revascularization
Thrombolysis In Myocardial Infarction
Abbreviations and Acronyms
BMS
bare-metal stent(s)
IRA
infarct-related artery
MACE
major adverse cardiac event(s)
PCI
percutaneous coronary intervention
ROC
receiver-operator characteristic
SES
sirolimus-eluting stent(s)
ST
stent thrombosis
STEMI
ST-segment elevation myocardial infarction
SXscore
SYNTAX score
TIMI
Thrombolysis In Myocardial Infarction
TVR
target vessel revascularization
Cited by (0)
Dr. Bolognese has received honoraria for lectures from Merck and Eli Lilly. Dr. Valgimigli has received honoraria for lectures/advisory board and research grants from Eli Lilly, Medtronic, Merck, and Iroko; and honoraria for advisory board from Cordis, Abbott, Eisai, AstraZeneca, The Medicines Company, Eli Lilly Co., Daiichi Sankyo, Inc., and Medtronic. All other authors report that they have no relationships to disclose.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.